Big Deal of the Day: Shire Buys Dyax

by | Nov 3, 2015 6:48 pm | Biotechnology, Pharmaceuticals

Shire plc (NASDAQ: SHPG) is on a buying binge in 2015. After agreeing to be acquired by AbbVie (NYSE: ABBV) for $54.7 billion in July 2014, the deal fell apart in October following the Treasury Department’s revised ruling on foreign domiciles. Shire management turned around and acquired rare disease drug maker NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) in January for $5.2 billion, then added prescription drug maker  Meritage Pharma, Inc. in February for $70 million. After a few months digesting those deals, Shire was back on the acquisition trail in August, paying $300 million for Foresight Biotherapeutics Inc., a clincal stage drug development company. Now it’s agreed to pay... Read More »

Q3:15 Health Care Dollars, vs. Q2:15

by | Nov 2, 2015 8:57 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we gave you the breakdown on how the third quarter of 2015 compared with the second quarter and the same quarter a year ago. Here’s how the dollars broke out, versus those quarters. SectorQ3:15Q2:15ChangeQ3:14Change Services Behavioral Health Care$550,000$190,700188%$335,00064% Home Health & Hospice$241,854$0n/a$410,000-41% Hospitals$2,069,865 $2,059,9000.5%$969,800113% Labs, MRI & Dialysis$826,600$1,507,650-45%$324,000155% Long-Term Care$4,175,656$4,141,9300.8%$9,686,200-57% Managed Care$98,000,000$147,00066566%$0n/a Physician Medical Groups$1,600,000$500,000220%$0n/a Rehabilitation $4,300$734,800-99%$163,450-97% Other Services$1,396,474$16,211,644-91%$1,026,40036%... Read More »

Q3:15 Health Care Deal Volume

by | Oct 26, 2015 9:15 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

We’re just about to publish our third quarter results this week, but wanted to give you a sneak preview of how the third quarter stacks up against Q2:15 and the same quarter a year ago. Here’s the chart. SectorQ3:15 DealsQ2:15 DealsChangeQ3:14 DealsChange Services Behavioral Health Care10667%4150% Home Health & Hospice9650%15-40% Hospitals332438%1974% Labs, MRI & Dialysis16157%8100% Long-Term Care906538%856% Managed Care12850%5140% Physician Medical Groups1522-32%147% Rehabilitation7617%540% Other Services464015%3628% Services subtotal23819224%19125% Technology Biotechnology413421%27%52% eHealth3334-3%34-3% Medical Devices31297%2619% Pharmaceuticals423811%67-37%... Read More »

Q3:15 Health Care M&A, by Spending

by | Oct 19, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we shared our data on health care M&A by sector in the third quarter of 2015. Here’s a look at the same sectors, by share of the dollars spent. If you’ve been following health care M&A at all, you won’t be surprised that the Managed Care sector (health insurers) accounts for about 50% of the $198 billion spent. That total, by the way, is also a new quarterly record. Look for The Health Care M&A Report, Third Quarter, for more in-depth analysis by sector. Read More »

Q3:15 Health Care M&A, By Sector

by | Oct 12, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Rehabilitation

Health care M&A in the third quarter was quite robust, with 385 transations reported across 13 sectors. That’s a new record for any third quarter, by the way. We’ll have the full break-out in The Health Care M&A Report, Third Quarter 2015, due to be published by the end of this month. In the meantime, here’s how the sectors fared in Q3:15. Read More »

Teva Can’t Stop Buying

by | Oct 5, 2015 8:59 am | Pharmaceuticals

With six acquisitions already on the books in 2015, Teva Pharmaceutical Industries (NYSE: TEVA) announced it would pay $2.3 billion for Representaciones e Investigaciones Médicas (Rimsa), a leading pharmaceutical manufacturing and distribution company in Mexico. Also associated with this deal is a portfolio of products and companies, intellectual property, assets and pharmaceutical patents in Latin America and Europe. With this acquisition, Teva becomes one of the top pharmaceutical companies in Mexico, which is the second largest market in Latin America and one of the top five emerging markets globally. The company expects the deal will yield substantial and achievable synergies and offer... Read More »